Larimar Therapeutics (LRMR) Income from Continuing Operations: 2012-2019
Historic Income from Continuing Operations for Larimar Therapeutics (LRMR) over the last 8 years, with Dec 2019 value amounting to -$45.4 million.
- Larimar Therapeutics' Income from Continuing Operations rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- Per Larimar Therapeutics' latest filing, its Income from Continuing Operations stood at -$45.4 million for FY2019, which was up 25.68% from -$61.1 million recorded in FY2018.
- Larimar Therapeutics' Income from Continuing Operations' 5-year high stood at -$45.4 million during FY2019, with a 5-year trough of -$74.2 million in FY2015.
- Moreover, its 3-year median value for Income from Continuing Operations was -$52.2 million (2017), whereas its average is -$52.9 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 103.94% in 2015, then climbed by 25.68% in 2019.
- Larimar Therapeutics' Income from Continuing Operations (Yearly) stood at -$74.2 million in 2015, then grew by 22.00% to -$57.9 million in 2016, then climbed by 9.84% to -$52.2 million in 2017, then fell by 17.18% to -$61.1 million in 2018, then grew by 25.68% to -$45.4 million in 2019.